| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oropharyngeal Neoplasms | 105 | 2023 | 1105 | 13.030 |
Why?
|
| Papillomavirus Infections | 81 | 2023 | 980 | 10.010 |
Why?
|
| Head and Neck Neoplasms | 164 | 2024 | 3976 | 8.580 |
Why?
|
| Carcinoma, Squamous Cell | 164 | 2023 | 5437 | 8.160 |
Why?
|
| Human papillomavirus 16 | 46 | 2022 | 256 | 4.710 |
Why?
|
| Papillomaviridae | 35 | 2023 | 624 | 4.060 |
Why?
|
| Thyroid Neoplasms | 43 | 2020 | 1866 | 4.020 |
Why?
|
| Polymorphism, Single Nucleotide | 75 | 2022 | 4549 | 3.260 |
Why?
|
| Alphapapillomavirus | 14 | 2022 | 171 | 3.190 |
Why?
|
| Polymorphism, Genetic | 50 | 2016 | 1450 | 3.040 |
Why?
|
| Alcohol Drinking | 37 | 2024 | 551 | 2.920 |
Why?
|
| Smoking | 56 | 2024 | 2440 | 2.880 |
Why?
|
| Mouth Neoplasms | 22 | 2020 | 713 | 2.610 |
Why?
|
| Genetic Predisposition to Disease | 87 | 2022 | 5539 | 2.530 |
Why?
|
| Salivary Gland Neoplasms | 12 | 2016 | 489 | 2.480 |
Why?
|
| Case-Control Studies | 109 | 2024 | 6100 | 2.150 |
Why?
|
| Middle Aged | 278 | 2023 | 86204 | 1.940 |
Why?
|
| Male | 291 | 2023 | 123000 | 1.700 |
Why?
|
| Genotype | 79 | 2022 | 4109 | 1.670 |
Why?
|
| Risk Factors | 115 | 2024 | 17523 | 1.570 |
Why?
|
| Carcinoma, Papillary | 16 | 2018 | 584 | 1.560 |
Why?
|
| Carcinoma | 22 | 2022 | 2578 | 1.550 |
Why?
|
| Female | 293 | 2023 | 141928 | 1.550 |
Why?
|
| Neoplasms, Second Primary | 17 | 2016 | 1350 | 1.540 |
Why?
|
| Humans | 368 | 2024 | 261506 | 1.460 |
Why?
|
| Laryngeal Neoplasms | 19 | 2023 | 518 | 1.440 |
Why?
|
| DNA Repair | 24 | 2017 | 1872 | 1.410 |
Why?
|
| Vaccination | 5 | 2022 | 1123 | 1.400 |
Why?
|
| Aged | 192 | 2023 | 70117 | 1.370 |
Why?
|
| Adult | 187 | 2023 | 77950 | 1.360 |
Why?
|
| Pharyngeal Neoplasms | 10 | 2013 | 133 | 1.350 |
Why?
|
| Papillomavirus Vaccines | 8 | 2022 | 195 | 1.320 |
Why?
|
| Antibodies, Viral | 5 | 2020 | 1320 | 1.210 |
Why?
|
| Incidence | 32 | 2021 | 5673 | 1.200 |
Why?
|
| Anus Neoplasms | 5 | 2022 | 411 | 1.170 |
Why?
|
| Neoplasm Recurrence, Local | 37 | 2023 | 10035 | 1.150 |
Why?
|
| DNA-Binding Proteins | 25 | 2018 | 4821 | 1.120 |
Why?
|
| Neck Dissection | 9 | 2020 | 290 | 1.000 |
Why?
|
| fas Receptor | 6 | 2016 | 185 | 0.980 |
Why?
|
| Aged, 80 and over | 93 | 2021 | 29902 | 0.960 |
Why?
|
| Promoter Regions, Genetic | 22 | 2017 | 3101 | 0.920 |
Why?
|
| Tongue Neoplasms | 6 | 2020 | 246 | 0.910 |
Why?
|
| MicroRNAs | 17 | 2019 | 2947 | 0.890 |
Why?
|
| Mouth Diseases | 3 | 2023 | 34 | 0.890 |
Why?
|
| Genetic Variation | 16 | 2018 | 2086 | 0.880 |
Why?
|
| DNA, Viral | 7 | 2020 | 694 | 0.870 |
Why?
|
| Tumor Virus Infections | 4 | 2019 | 224 | 0.850 |
Why?
|
| Nasopharyngeal Neoplasms | 4 | 2016 | 323 | 0.840 |
Why?
|
| Prognosis | 51 | 2023 | 21713 | 0.820 |
Why?
|
| Uterine Cervical Neoplasms | 9 | 2022 | 1833 | 0.820 |
Why?
|
| Genes, BRCA1 | 3 | 2017 | 387 | 0.810 |
Why?
|
| Retrospective Studies | 70 | 2023 | 37905 | 0.800 |
Why?
|
| Thyroidectomy | 8 | 2020 | 486 | 0.800 |
Why?
|
| Hemangiosarcoma | 5 | 2023 | 234 | 0.790 |
Why?
|
| Sexual Behavior | 3 | 2018 | 310 | 0.790 |
Why?
|
| Lymphocytes | 12 | 2020 | 1234 | 0.780 |
Why?
|
| Carcinoma, Adenoid Cystic | 4 | 2011 | 421 | 0.770 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2011 | 388 | 0.760 |
Why?
|
| Adenocarcinoma, Follicular | 4 | 2018 | 132 | 0.760 |
Why?
|
| Neoplasm Staging | 31 | 2019 | 13658 | 0.740 |
Why?
|
| Radiotherapy, Intensity-Modulated | 14 | 2021 | 2104 | 0.740 |
Why?
|
| Oropharynx | 5 | 2017 | 74 | 0.730 |
Why?
|
| Penile Neoplasms | 2 | 2021 | 161 | 0.720 |
Why?
|
| Odds Ratio | 29 | 2016 | 2316 | 0.710 |
Why?
|
| Logistic Models | 25 | 2017 | 3441 | 0.710 |
Why?
|
| Early Detection of Cancer | 5 | 2021 | 1258 | 0.710 |
Why?
|
| Genes, p16 | 3 | 2016 | 125 | 0.710 |
Why?
|
| 3' Untranslated Regions | 10 | 2019 | 343 | 0.710 |
Why?
|
| Xerostomia | 5 | 2022 | 190 | 0.700 |
Why?
|
| Texas | 23 | 2021 | 6311 | 0.700 |
Why?
|
| Gamma Rays | 3 | 2005 | 242 | 0.680 |
Why?
|
| Tobacco Products | 1 | 2020 | 120 | 0.670 |
Why?
|
| Adolescent | 60 | 2023 | 31252 | 0.650 |
Why?
|
| Lymph Nodes | 10 | 2019 | 2967 | 0.650 |
Why?
|
| DNA Helicases | 6 | 2018 | 434 | 0.640 |
Why?
|
| Genes, p53 | 10 | 2013 | 1090 | 0.620 |
Why?
|
| Disease-Free Survival | 31 | 2020 | 10001 | 0.620 |
Why?
|
| Smoking Cessation | 4 | 2020 | 712 | 0.620 |
Why?
|
| Mass Screening | 3 | 2021 | 1509 | 0.620 |
Why?
|
| Social Class | 3 | 2014 | 310 | 0.610 |
Why?
|
| Laryngectomy | 7 | 2023 | 242 | 0.600 |
Why?
|
| Sex Distribution | 8 | 2019 | 495 | 0.580 |
Why?
|
| Risk | 29 | 2017 | 1972 | 0.580 |
Why?
|
| Fanconi Anemia | 1 | 2017 | 88 | 0.580 |
Why?
|
| Nuclear Proteins | 16 | 2017 | 3343 | 0.570 |
Why?
|
| Oncogene Proteins, Viral | 5 | 2018 | 133 | 0.570 |
Why?
|
| Follow-Up Studies | 32 | 2021 | 14889 | 0.560 |
Why?
|
| Risk Assessment | 24 | 2020 | 6869 | 0.560 |
Why?
|
| Survival Analysis | 23 | 2019 | 9180 | 0.560 |
Why?
|
| Global Health | 6 | 2018 | 657 | 0.550 |
Why?
|
| Cancer Survivors | 7 | 2022 | 650 | 0.550 |
Why?
|
| Young Adult | 44 | 2020 | 21445 | 0.550 |
Why?
|
| Prevalence | 14 | 2023 | 3260 | 0.550 |
Why?
|
| In Situ Hybridization | 5 | 2018 | 1037 | 0.540 |
Why?
|
| Kaplan-Meier Estimate | 20 | 2020 | 6207 | 0.540 |
Why?
|
| Tobacco Use Disorder | 3 | 2013 | 284 | 0.530 |
Why?
|
| Oral Hygiene | 1 | 2015 | 20 | 0.530 |
Why?
|
| Oral Health | 1 | 2015 | 18 | 0.530 |
Why?
|
| Haplotypes | 10 | 2012 | 856 | 0.530 |
Why?
|
| DNA Breaks, Double-Stranded | 4 | 2017 | 316 | 0.530 |
Why?
|
| Neoplasms, Squamous Cell | 3 | 2011 | 87 | 0.520 |
Why?
|
| Proportional Hazards Models | 16 | 2023 | 4988 | 0.520 |
Why?
|
| Lymphatic Metastasis | 15 | 2019 | 4844 | 0.510 |
Why?
|
| Age Distribution | 9 | 2018 | 698 | 0.510 |
Why?
|
| United States | 31 | 2021 | 15433 | 0.510 |
Why?
|
| Glutathione Transferase | 5 | 2010 | 359 | 0.510 |
Why?
|
| Neoadjuvant Therapy | 7 | 2020 | 4975 | 0.500 |
Why?
|
| Cohort Studies | 26 | 2020 | 9244 | 0.500 |
Why?
|
| Survival Rate | 24 | 2020 | 12221 | 0.500 |
Why?
|
| Prospective Studies | 22 | 2023 | 12873 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 7 | 2017 | 507 | 0.480 |
Why?
|
| Tumor Suppressor Proteins | 12 | 2013 | 1823 | 0.470 |
Why?
|
| Osteosarcoma | 4 | 2009 | 929 | 0.470 |
Why?
|
| Tumor Suppressor Protein p14ARF | 5 | 2013 | 97 | 0.460 |
Why?
|
| Cotinine | 3 | 2008 | 41 | 0.450 |
Why?
|
| Endonucleases | 5 | 2013 | 178 | 0.450 |
Why?
|
| Human papillomavirus 18 | 3 | 2018 | 43 | 0.450 |
Why?
|
| Temporal Bone | 2 | 2012 | 102 | 0.440 |
Why?
|
| Reference Values | 10 | 2017 | 1099 | 0.440 |
Why?
|
| Free Tissue Flaps | 4 | 2022 | 372 | 0.440 |
Why?
|
| Facial Neoplasms | 2 | 2010 | 84 | 0.440 |
Why?
|
| Vitamins | 1 | 2013 | 157 | 0.440 |
Why?
|
| Combined Modality Therapy | 17 | 2023 | 8865 | 0.430 |
Why?
|
| Cross-Sectional Studies | 15 | 2023 | 4314 | 0.430 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 3 | 2020 | 259 | 0.430 |
Why?
|
| Self Report | 2 | 2017 | 756 | 0.420 |
Why?
|
| SEER Program | 6 | 2021 | 1000 | 0.420 |
Why?
|
| Fas Ligand Protein | 4 | 2016 | 150 | 0.420 |
Why?
|
| Salivary Glands, Minor | 1 | 2011 | 33 | 0.420 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2019 | 2488 | 0.420 |
Why?
|
| Biomarkers, Tumor | 23 | 2020 | 10331 | 0.420 |
Why?
|
| Histiocytoma, Malignant Fibrous | 2 | 2012 | 51 | 0.410 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2012 | 153 | 0.400 |
Why?
|
| Proton Therapy | 6 | 2020 | 1577 | 0.400 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2010 | 69 | 0.400 |
Why?
|
| Registries | 8 | 2016 | 2170 | 0.400 |
Why?
|
| Larynx, Artificial | 4 | 2012 | 43 | 0.390 |
Why?
|
| Family Health | 2 | 2011 | 325 | 0.390 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2008 | 105 | 0.390 |
Why?
|
| Polymerase Chain Reaction | 15 | 2015 | 3203 | 0.390 |
Why?
|
| Genome-Wide Association Study | 9 | 2022 | 2265 | 0.380 |
Why?
|
| Skin Neoplasms | 8 | 2023 | 4654 | 0.380 |
Why?
|
| Sex Factors | 13 | 2018 | 2139 | 0.380 |
Why?
|
| Bone Neoplasms | 4 | 2016 | 2576 | 0.380 |
Why?
|
| Binding Sites | 12 | 2019 | 2171 | 0.380 |
Why?
|
| Multivariate Analysis | 14 | 2015 | 4298 | 0.380 |
Why?
|
| Treatment Outcome | 32 | 2023 | 32848 | 0.370 |
Why?
|
| Deglutition Disorders | 4 | 2020 | 447 | 0.370 |
Why?
|
| Hepatitis C, Chronic | 4 | 2019 | 451 | 0.370 |
Why?
|
| Gene Frequency | 14 | 2019 | 1163 | 0.370 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2018 | 292 | 0.360 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2017 | 2231 | 0.360 |
Why?
|
| Hepacivirus | 5 | 2020 | 397 | 0.360 |
Why?
|
| Osteoradionecrosis | 3 | 2017 | 123 | 0.360 |
Why?
|
| Intestinal Polyposis | 1 | 2009 | 30 | 0.360 |
Why?
|
| Genetic Association Studies | 13 | 2017 | 1084 | 0.350 |
Why?
|
| Jaw Neoplasms | 1 | 2009 | 17 | 0.350 |
Why?
|
| Codon | 8 | 2011 | 241 | 0.350 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2022 | 476 | 0.340 |
Why?
|
| Genital Neoplasms, Male | 1 | 2009 | 44 | 0.340 |
Why?
|
| Residence Characteristics | 1 | 2012 | 348 | 0.340 |
Why?
|
| Dietary Supplements | 1 | 2013 | 558 | 0.340 |
Why?
|
| Scalp | 1 | 2010 | 156 | 0.340 |
Why?
|
| Matched-Pair Analysis | 5 | 2014 | 103 | 0.340 |
Why?
|
| Chi-Square Distribution | 7 | 2011 | 1323 | 0.340 |
Why?
|
| Ear Canal | 1 | 2008 | 31 | 0.320 |
Why?
|
| Confidence Intervals | 9 | 2017 | 756 | 0.320 |
Why?
|
| Hepatitis C Antibodies | 2 | 2020 | 41 | 0.320 |
Why?
|
| Famous Persons | 1 | 2008 | 23 | 0.320 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2017 | 1489 | 0.320 |
Why?
|
| Primary Prevention | 2 | 2013 | 255 | 0.320 |
Why?
|
| Punctures | 4 | 2012 | 104 | 0.320 |
Why?
|
| Ear Neoplasms | 1 | 2008 | 59 | 0.310 |
Why?
|
| Diet | 3 | 2013 | 1440 | 0.310 |
Why?
|
| Thyroid Gland | 4 | 2020 | 355 | 0.310 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 945 | 0.310 |
Why?
|
| Age Factors | 14 | 2020 | 5377 | 0.310 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2009 | 221 | 0.300 |
Why?
|
| Immunohistochemistry | 10 | 2018 | 7548 | 0.300 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2008 | 129 | 0.300 |
Why?
|
| Re-Irradiation | 2 | 2020 | 163 | 0.300 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2022 | 799 | 0.300 |
Why?
|
| Occupational Exposure | 2 | 2008 | 244 | 0.290 |
Why?
|
| Liposarcoma | 1 | 2009 | 214 | 0.290 |
Why?
|
| Sarcoma | 5 | 2012 | 1725 | 0.280 |
Why?
|
| Medicaid | 2 | 2019 | 279 | 0.280 |
Why?
|
| Cigarette Smoking | 2 | 2019 | 88 | 0.280 |
Why?
|
| Sarcoma, Synovial | 1 | 2007 | 119 | 0.280 |
Why?
|
| Molecular Epidemiology | 2 | 2009 | 246 | 0.280 |
Why?
|
| Biopsy, Needle | 5 | 2017 | 1363 | 0.270 |
Why?
|
| Cell Cycle Proteins | 9 | 2019 | 2045 | 0.270 |
Why?
|
| Hypopharyngeal Neoplasms | 3 | 2016 | 82 | 0.270 |
Why?
|
| Proteins | 3 | 2002 | 1963 | 0.270 |
Why?
|
| Interleukin-1alpha | 2 | 2016 | 56 | 0.270 |
Why?
|
| Gastrostomy | 2 | 2015 | 180 | 0.270 |
Why?
|
| Tracheal Neoplasms | 1 | 2005 | 42 | 0.270 |
Why?
|
| Wound Healing | 1 | 2010 | 815 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 15862 | 0.260 |
Why?
|
| Neurothekeoma | 1 | 2005 | 10 | 0.260 |
Why?
|
| Protein C Inhibitor | 2 | 2016 | 4 | 0.260 |
Why?
|
| Secondary Prevention | 2 | 2020 | 329 | 0.260 |
Why?
|
| Carcinogens | 5 | 2014 | 384 | 0.260 |
Why?
|
| Disease Progression | 11 | 2015 | 6682 | 0.260 |
Why?
|
| E2F2 Transcription Factor | 2 | 2017 | 27 | 0.260 |
Why?
|
| Surgical Flaps | 2 | 2010 | 927 | 0.260 |
Why?
|
| Radiotherapy Dosage | 9 | 2020 | 3842 | 0.250 |
Why?
|
| Radiation Injuries | 5 | 2019 | 1411 | 0.250 |
Why?
|
| Radiotherapy, Conformal | 3 | 2020 | 902 | 0.250 |
Why?
|
| Socioeconomic Factors | 5 | 2015 | 1225 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 1265 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2015 | 3552 | 0.240 |
Why?
|
| Survivors | 6 | 2022 | 1031 | 0.240 |
Why?
|
| Papillomavirus E7 Proteins | 3 | 2013 | 64 | 0.240 |
Why?
|
| Exons | 6 | 2008 | 1328 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2014 | 1538 | 0.240 |
Why?
|
| G2 Phase | 1 | 2004 | 206 | 0.240 |
Why?
|
| Cost of Illness | 2 | 2020 | 498 | 0.240 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 598 | 0.230 |
Why?
|
| Repressor Proteins | 3 | 2013 | 1664 | 0.230 |
Why?
|
| Prosthesis Failure | 4 | 2012 | 206 | 0.230 |
Why?
|
| Child | 17 | 2020 | 29154 | 0.230 |
Why?
|
| DNA Adducts | 3 | 2010 | 210 | 0.230 |
Why?
|
| Cancer Care Facilities | 6 | 2020 | 884 | 0.230 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2022 | 690 | 0.230 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2018 | 192 | 0.230 |
Why?
|
| Quality Assurance, Health Care | 2 | 2020 | 585 | 0.230 |
Why?
|
| E2F1 Transcription Factor | 2 | 2016 | 206 | 0.230 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 354 | 0.230 |
Why?
|
| Pilot Projects | 7 | 2023 | 2803 | 0.230 |
Why?
|
| Paclitaxel | 2 | 2011 | 1996 | 0.220 |
Why?
|
| Anus Diseases | 1 | 2022 | 29 | 0.220 |
Why?
|
| Genetic Loci | 2 | 2017 | 481 | 0.220 |
Why?
|
| Tonsillar Neoplasms | 2 | 2015 | 80 | 0.220 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 4 | 2013 | 69 | 0.220 |
Why?
|
| Telomere | 2 | 2019 | 505 | 0.220 |
Why?
|
| Rad51 Recombinase | 2 | 2017 | 126 | 0.220 |
Why?
|
| Smokers | 2 | 2020 | 143 | 0.220 |
Why?
|
| Vulvar Neoplasms | 2 | 2022 | 236 | 0.210 |
Why?
|
| Transcription Factors | 5 | 2013 | 5270 | 0.210 |
Why?
|
| Cocaine | 1 | 2024 | 233 | 0.210 |
Why?
|
| Larynx | 1 | 2023 | 134 | 0.210 |
Why?
|
| Tinnitus | 1 | 2022 | 38 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.210 |
Why?
|
| Hypoparathyroidism | 2 | 2020 | 49 | 0.210 |
Why?
|
| Epidemics | 2 | 2013 | 63 | 0.210 |
Why?
|
| Behavior Therapy | 1 | 2004 | 298 | 0.210 |
Why?
|
| Chemoradiotherapy | 8 | 2019 | 1946 | 0.200 |
Why?
|
| Marijuana Smoking | 2 | 2013 | 39 | 0.200 |
Why?
|
| Postoperative Complications | 10 | 2022 | 5542 | 0.200 |
Why?
|
| Surveys and Questionnaires | 9 | 2021 | 5687 | 0.200 |
Why?
|
| Triage | 2 | 2020 | 252 | 0.200 |
Why?
|
| Mouthwashes | 1 | 2021 | 41 | 0.200 |
Why?
|
| Speech, Alaryngeal | 2 | 2011 | 24 | 0.200 |
Why?
|
| Voice Disorders | 1 | 2021 | 39 | 0.200 |
Why?
|
| Watchful Waiting | 2 | 2021 | 289 | 0.200 |
Why?
|
| Organ Transplantation | 1 | 2023 | 191 | 0.200 |
Why?
|
| Cisplatin | 3 | 2018 | 2432 | 0.190 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2021 | 1217 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 661 | 0.190 |
Why?
|
| Speech Disorders | 1 | 2021 | 91 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 852 | 0.190 |
Why?
|
| International Cooperation | 2 | 2013 | 323 | 0.190 |
Why?
|
| Quality of Life | 9 | 2022 | 4532 | 0.190 |
Why?
|
| Hearing Loss | 1 | 2022 | 153 | 0.190 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 2 | 2018 | 46 | 0.190 |
Why?
|
| Immunoglobulin G | 3 | 2015 | 1021 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2012 | 528 | 0.190 |
Why?
|
| Positron-Emission Tomography | 5 | 2014 | 2173 | 0.190 |
Why?
|
| Pharyngeal Diseases | 1 | 2020 | 53 | 0.190 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 2 | 2017 | 40 | 0.190 |
Why?
|
| Cranial Nerve Diseases | 1 | 2021 | 73 | 0.190 |
Why?
|
| Mass Vaccination | 1 | 2020 | 21 | 0.190 |
Why?
|
| Tobacco Use | 2 | 2018 | 54 | 0.190 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2020 | 34 | 0.190 |
Why?
|
| Tumor Protein p73 | 8 | 2013 | 105 | 0.190 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 141 | 0.190 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 46 | 0.180 |
Why?
|
| Medical History Taking | 2 | 2011 | 173 | 0.180 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 3 | 2009 | 62 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 1209 | 0.180 |
Why?
|
| Vaginal Smears | 1 | 2021 | 192 | 0.180 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 83 | 0.180 |
Why?
|
| Direct Service Costs | 1 | 2019 | 12 | 0.180 |
Why?
|
| Caspase 3 | 2 | 2012 | 471 | 0.180 |
Why?
|
| Cetuximab | 2 | 2018 | 472 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2019 | 7551 | 0.170 |
Why?
|
| Apoptosis | 5 | 2016 | 7591 | 0.170 |
Why?
|
| RNA, Messenger | 7 | 2022 | 6150 | 0.170 |
Why?
|
| Health Personnel | 2 | 2021 | 625 | 0.170 |
Why?
|
| Multifactorial Inheritance | 1 | 2020 | 148 | 0.170 |
Why?
|
| Age of Onset | 3 | 2017 | 827 | 0.170 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2019 | 15 | 0.170 |
Why?
|
| Capsid Proteins | 2 | 2018 | 185 | 0.170 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2021 | 219 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2018 | 1226 | 0.170 |
Why?
|
| Markov Chains | 1 | 2019 | 175 | 0.170 |
Why?
|
| Comorbidity | 5 | 2018 | 2352 | 0.170 |
Why?
|
| Glossectomy | 2 | 2011 | 40 | 0.170 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 487 | 0.170 |
Why?
|
| Genital Neoplasms, Female | 2 | 2019 | 735 | 0.170 |
Why?
|
| Neoplasm Proteins | 5 | 2013 | 3230 | 0.170 |
Why?
|
| World Health Organization | 2 | 2010 | 316 | 0.170 |
Why?
|
| Academic Medical Centers | 3 | 2017 | 672 | 0.170 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1945 | 0.170 |
Why?
|
| History, 21st Century | 2 | 2013 | 441 | 0.170 |
Why?
|
| Neck Muscles | 1 | 2018 | 38 | 0.160 |
Why?
|
| Alleles | 6 | 2013 | 2437 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2019 | 627 | 0.160 |
Why?
|
| Liver Neoplasms | 3 | 2020 | 4557 | 0.160 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 2 | 2008 | 96 | 0.160 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2017 | 10 | 0.160 |
Why?
|
| Anal Canal | 1 | 2019 | 238 | 0.160 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 2 | 2008 | 66 | 0.160 |
Why?
|
| Health Care Costs | 2 | 2020 | 674 | 0.160 |
Why?
|
| Patient Preference | 1 | 2020 | 218 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 527 | 0.160 |
Why?
|
| Fanconi Anemia Complementation Group L Protein | 1 | 2017 | 1 | 0.160 |
Why?
|
| Fanconi Anemia Complementation Group E Protein | 1 | 2017 | 3 | 0.160 |
Why?
|
| Surgical Oncology | 1 | 2020 | 190 | 0.150 |
Why?
|
| Telomerase | 2 | 2011 | 525 | 0.150 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2010 | 33 | 0.150 |
Why?
|
| Adenoma, Oxyphilic | 3 | 2012 | 82 | 0.150 |
Why?
|
| 5' Untranslated Regions | 3 | 2008 | 93 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 199 | 0.150 |
Why?
|
| Recombinases | 1 | 2017 | 29 | 0.150 |
Why?
|
| Muscle Neoplasms | 1 | 2018 | 109 | 0.150 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2017 | 41 | 0.150 |
Why?
|
| DNA, Neoplasm | 6 | 2012 | 1910 | 0.150 |
Why?
|
| Enteral Nutrition | 2 | 2016 | 316 | 0.150 |
Why?
|
| Mouth | 1 | 2018 | 122 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 250 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2403 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 8873 | 0.150 |
Why?
|
| Child, Preschool | 7 | 2020 | 16273 | 0.150 |
Why?
|
| Men | 1 | 2016 | 9 | 0.150 |
Why?
|
| Tonsillectomy | 2 | 2016 | 102 | 0.150 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2017 | 75 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 573 | 0.150 |
Why?
|
| Microsatellite Repeats | 4 | 2012 | 575 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2016 | 3890 | 0.140 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 14289 | 0.140 |
Why?
|
| Microbiota | 1 | 2023 | 547 | 0.140 |
Why?
|
| Patient Selection | 3 | 2020 | 2055 | 0.140 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 2283 | 0.140 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2016 | 9 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2017 | 1824 | 0.140 |
Why?
|
| Salivary Gland Diseases | 2 | 2008 | 10 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 2027 | 0.140 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2016 | 79 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 502 | 0.140 |
Why?
|
| Cell Differentiation | 5 | 2012 | 4078 | 0.140 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 28 | 0.140 |
Why?
|
| DNA Glycosylases | 2 | 2008 | 93 | 0.140 |
Why?
|
| Neutrophils | 1 | 2020 | 835 | 0.140 |
Why?
|
| Thyroid Diseases | 2 | 2008 | 85 | 0.140 |
Why?
|
| Body Mass Index | 4 | 2014 | 2203 | 0.140 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 980 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2017 | 250 | 0.140 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2016 | 94 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 246 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2020 | 785 | 0.130 |
Why?
|
| Spouses | 1 | 2017 | 134 | 0.130 |
Why?
|
| Recombinational DNA Repair | 1 | 2016 | 79 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 447 | 0.130 |
Why?
|
| Vietnam | 1 | 2015 | 56 | 0.130 |
Why?
|
| Receptors, Odorant | 1 | 2015 | 47 | 0.130 |
Why?
|
| Sensitivity and Specificity | 4 | 2021 | 4971 | 0.130 |
Why?
|
| RNA Helicases | 1 | 2015 | 101 | 0.130 |
Why?
|
| Health Promotion | 1 | 2019 | 502 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 358 | 0.130 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2015 | 44 | 0.130 |
Why?
|
| Europe | 4 | 2011 | 649 | 0.130 |
Why?
|
| Helicobacter pylori | 1 | 2005 | 1295 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 437 | 0.130 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 489 | 0.130 |
Why?
|
| Helicobacter Infections | 1 | 2005 | 1216 | 0.130 |
Why?
|
| ROC Curve | 5 | 2020 | 1183 | 0.130 |
Why?
|
| Salvage Therapy | 4 | 2023 | 2054 | 0.130 |
Why?
|
| Carboplatin | 3 | 2015 | 823 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2020 | 524 | 0.130 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 1046 | 0.120 |
Why?
|
| Causality | 2 | 2014 | 178 | 0.120 |
Why?
|
| Photons | 1 | 2018 | 507 | 0.120 |
Why?
|
| Thyroglobulin | 1 | 2014 | 62 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 665 | 0.120 |
Why?
|
| Zinc Fingers | 1 | 2015 | 205 | 0.120 |
Why?
|
| Consensus | 2 | 2020 | 978 | 0.120 |
Why?
|
| Polymorphism, Restriction Fragment Length | 4 | 2011 | 239 | 0.120 |
Why?
|
| Heterozygote | 1 | 2017 | 1020 | 0.120 |
Why?
|
| Deglutition | 2 | 2020 | 171 | 0.120 |
Why?
|
| Education | 1 | 2014 | 112 | 0.120 |
Why?
|
| Pandemics | 2 | 2020 | 1559 | 0.120 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2013 | 43 | 0.120 |
Why?
|
| Research Design | 2 | 2019 | 1544 | 0.120 |
Why?
|
| Ethanol | 2 | 2022 | 264 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 481 | 0.120 |
Why?
|
| Receptors, Nicotinic | 1 | 2015 | 190 | 0.120 |
Why?
|
| Time Factors | 6 | 2020 | 12926 | 0.120 |
Why?
|
| DNA Repair Enzymes | 3 | 2011 | 237 | 0.120 |
Why?
|
| Income | 1 | 2014 | 222 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 1493 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 2 | 2008 | 334 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1039 | 0.110 |
Why?
|
| Linkage Disequilibrium | 2 | 2012 | 460 | 0.110 |
Why?
|
| Telomere Homeostasis | 1 | 2013 | 73 | 0.110 |
Why?
|
| Seroepidemiologic Studies | 2 | 2016 | 129 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2012 | 287 | 0.110 |
Why?
|
| Group Processes | 1 | 2012 | 53 | 0.110 |
Why?
|
| Epigenomics | 1 | 2014 | 266 | 0.110 |
Why?
|
| Dinucleotide Repeats | 1 | 2012 | 10 | 0.110 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 833 | 0.110 |
Why?
|
| Induction Chemotherapy | 2 | 2016 | 669 | 0.110 |
Why?
|
| Iodine Radioisotopes | 1 | 2014 | 371 | 0.110 |
Why?
|
| Skull Neoplasms | 1 | 2012 | 67 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2018 | 1171 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 3719 | 0.110 |
Why?
|
| Mandibular Diseases | 1 | 2012 | 45 | 0.110 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 60 | 0.100 |
Why?
|
| Regression Analysis | 3 | 2020 | 1546 | 0.100 |
Why?
|
| Carotid Sinus | 1 | 2011 | 10 | 0.100 |
Why?
|
| Databases, Factual | 3 | 2020 | 2218 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 2483 | 0.100 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2011 | 13 | 0.100 |
Why?
|
| Urban Population | 1 | 2013 | 269 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2012 | 110 | 0.100 |
Why?
|
| Veterans | 2 | 2020 | 1641 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 778 | 0.100 |
Why?
|
| Pharyngectomy | 3 | 2020 | 44 | 0.100 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 716 | 0.100 |
Why?
|
| Bayes Theorem | 3 | 2021 | 1021 | 0.100 |
Why?
|
| Pneumonia, Aspiration | 1 | 2011 | 41 | 0.100 |
Why?
|
| Neoplasm Metastasis | 4 | 2009 | 5112 | 0.100 |
Why?
|
| Rhabdomyosarcoma | 2 | 2006 | 341 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2015 | 636 | 0.100 |
Why?
|
| Neoplasms | 3 | 2017 | 15193 | 0.100 |
Why?
|
| Ifosfamide | 1 | 2011 | 344 | 0.100 |
Why?
|
| Mandible | 1 | 2012 | 188 | 0.100 |
Why?
|
| Ultrasonography | 2 | 2014 | 1863 | 0.100 |
Why?
|
| Demography | 1 | 2012 | 435 | 0.100 |
Why?
|
| Rural Population | 1 | 2013 | 281 | 0.100 |
Why?
|
| Obesity | 2 | 2014 | 2884 | 0.090 |
Why?
|
| Biomarkers | 2 | 2020 | 5047 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 317 | 0.090 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 1742 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 60 | 0.090 |
Why?
|
| Observation | 1 | 2010 | 48 | 0.090 |
Why?
|
| Overweight | 2 | 2014 | 484 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2009 | 9 | 0.090 |
Why?
|
| Interleukin-10 | 1 | 2013 | 478 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2019 | 1423 | 0.090 |
Why?
|
| Linear Models | 2 | 2017 | 1085 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 3981 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2020 | 2307 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2011 | 231 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2594 | 0.090 |
Why?
|
| Caspase 8 | 1 | 2010 | 145 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2019 | 1335 | 0.090 |
Why?
|
| Speech Intelligibility | 1 | 2009 | 40 | 0.090 |
Why?
|
| Carcinoma, Basosquamous | 1 | 2009 | 12 | 0.090 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 172 | 0.090 |
Why?
|
| Thinness | 1 | 2010 | 82 | 0.090 |
Why?
|
| Patient Positioning | 1 | 2011 | 195 | 0.090 |
Why?
|
| Eye Neoplasms | 1 | 2011 | 247 | 0.090 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2009 | 73 | 0.090 |
Why?
|
| Marital Status | 1 | 2009 | 98 | 0.080 |
Why?
|
| Prosthesis Implantation | 4 | 2012 | 263 | 0.080 |
Why?
|
| Alcoholic Beverages | 1 | 2008 | 22 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 630 | 0.080 |
Why?
|
| Probability | 3 | 2010 | 866 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2012 | 291 | 0.080 |
Why?
|
| Nutrition Surveys | 2 | 2023 | 295 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 621 | 0.080 |
Why?
|
| Aldehyde Dehydrogenase | 2 | 2011 | 103 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 1070 | 0.080 |
Why?
|
| Otologic Surgical Procedures | 1 | 2008 | 33 | 0.080 |
Why?
|
| Poverty | 1 | 2012 | 471 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.080 |
Why?
|
| Microsurgery | 1 | 2010 | 244 | 0.080 |
Why?
|
| Genomic Instability | 1 | 2011 | 519 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2291 | 0.080 |
Why?
|
| Dronabinol | 1 | 2008 | 35 | 0.080 |
Why?
|
| Health Services Research | 1 | 2009 | 233 | 0.080 |
Why?
|
| DNA Damage | 2 | 2007 | 1954 | 0.080 |
Why?
|
| Benzopyrenes | 1 | 2007 | 11 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2008 | 154 | 0.080 |
Why?
|
| ADP Ribose Transferases | 1 | 2007 | 28 | 0.080 |
Why?
|
| Inclusion Bodies | 1 | 2007 | 76 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 1058 | 0.080 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2007 | 41 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 1016 | 0.080 |
Why?
|
| Parathyroid Glands | 1 | 2007 | 127 | 0.070 |
Why?
|
| Chromosomal Instability | 1 | 2008 | 233 | 0.070 |
Why?
|
| Immunoassay | 1 | 2008 | 216 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 11538 | 0.070 |
Why?
|
| Mutagens | 1 | 2007 | 187 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 367 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 761 | 0.070 |
Why?
|
| Mutagenesis, Insertional | 3 | 2016 | 218 | 0.070 |
Why?
|
| Heart Arrest | 1 | 2011 | 358 | 0.070 |
Why?
|
| Oxidoreductases | 1 | 2007 | 171 | 0.070 |
Why?
|
| Latin America | 3 | 2013 | 115 | 0.070 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2007 | 137 | 0.070 |
Why?
|
| Eyelid Neoplasms | 1 | 2008 | 191 | 0.070 |
Why?
|
| Genes, Retinoblastoma | 1 | 2006 | 86 | 0.070 |
Why?
|
| Cause of Death | 2 | 2020 | 752 | 0.070 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2005 | 9 | 0.070 |
Why?
|
| Medical Records | 1 | 2007 | 415 | 0.070 |
Why?
|
| Parents | 1 | 2012 | 998 | 0.070 |
Why?
|
| Loss of Heterozygosity | 2 | 2004 | 602 | 0.070 |
Why?
|
| Depression | 1 | 2016 | 1715 | 0.070 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2008 | 310 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2008 | 574 | 0.070 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2005 | 14 | 0.070 |
Why?
|
| Mandibular Neoplasms | 1 | 2006 | 76 | 0.070 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2005 | 24 | 0.070 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2005 | 16 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8223 | 0.070 |
Why?
|
| Radiopharmaceuticals | 4 | 2013 | 1301 | 0.070 |
Why?
|
| Germany | 2 | 2016 | 111 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 78 | 0.060 |
Why?
|
| Trachea | 3 | 2011 | 259 | 0.060 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2005 | 76 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2005 | 102 | 0.060 |
Why?
|
| Thymidylate Synthase | 1 | 2004 | 53 | 0.060 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2005 | 60 | 0.060 |
Why?
|
| Homozygote | 3 | 2013 | 717 | 0.060 |
Why?
|
| Esophageal Neoplasms | 2 | 2016 | 3168 | 0.060 |
Why?
|
| Receptors, Calcitriol | 1 | 2005 | 134 | 0.060 |
Why?
|
| Sequence Deletion | 3 | 2016 | 875 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 1129 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 703 | 0.060 |
Why?
|
| Cell Death | 1 | 2006 | 671 | 0.060 |
Why?
|
| India | 1 | 2004 | 301 | 0.060 |
Why?
|
| Algorithms | 3 | 2020 | 3890 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 448 | 0.060 |
Why?
|
| Neck | 2 | 2022 | 383 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2017 | 1391 | 0.060 |
Why?
|
| Esophagus | 3 | 2011 | 553 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 2341 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 14551 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4892 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 6009 | 0.060 |
Why?
|
| Genetic Markers | 3 | 2012 | 974 | 0.060 |
Why?
|
| Infant | 2 | 2020 | 13310 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2013 | 1763 | 0.060 |
Why?
|
| Parathyroid Neoplasms | 1 | 2004 | 185 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 380 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2005 | 370 | 0.050 |
Why?
|
| Fatigue | 2 | 2022 | 1239 | 0.050 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2022 | 12 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2022 | 22 | 0.050 |
Why?
|
| Awards and Prizes | 1 | 2004 | 98 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 726 | 0.050 |
Why?
|
| Cytokines | 1 | 2011 | 2809 | 0.050 |
Why?
|
| Decision Making | 1 | 2010 | 1287 | 0.050 |
Why?
|
| Disease Management | 2 | 2018 | 1052 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2010 | 2022 | 0.050 |
Why?
|
| Base Sequence | 4 | 2011 | 4917 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4320 | 0.050 |
Why?
|
| DNA | 3 | 2023 | 2693 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2018 | 5637 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2007 | 2359 | 0.050 |
Why?
|
| Cocarcinogenesis | 2 | 2011 | 50 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 490 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 54 | 0.050 |
Why?
|
| Iceland | 1 | 2020 | 12 | 0.050 |
Why?
|
| Vagina | 1 | 2022 | 317 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 629 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 1960 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 3639 | 0.050 |
Why?
|
| Health Behavior | 1 | 2004 | 603 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2020 | 1113 | 0.050 |
Why?
|
| Skull Base Neoplasms | 1 | 2004 | 314 | 0.040 |
Why?
|
| Developing Countries | 1 | 2022 | 315 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 95 | 0.040 |
Why?
|
| Penetrance | 1 | 2020 | 126 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2010 | 2819 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 748 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 257 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2021 | 253 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 383 | 0.040 |
Why?
|
| Parotid Gland | 1 | 2019 | 112 | 0.040 |
Why?
|
| Models, Biological | 3 | 2019 | 3254 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 177 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 684 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 486 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2022 | 487 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 68 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 175 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 374 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2022 | 862 | 0.040 |
Why?
|
| Pharynx | 1 | 2019 | 153 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2018 | 136 | 0.040 |
Why?
|
| Oximes | 1 | 2019 | 175 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2018 | 114 | 0.040 |
Why?
|
| Prosthesis Design | 2 | 2011 | 749 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 226 | 0.040 |
Why?
|
| Gene Expression | 3 | 2015 | 3570 | 0.040 |
Why?
|
| Computational Biology | 2 | 2020 | 1271 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 205 | 0.040 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2017 | 49 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 3251 | 0.040 |
Why?
|
| DNA Primers | 2 | 2011 | 1399 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 2292 | 0.040 |
Why?
|
| Pituitary Hormones | 1 | 2017 | 14 | 0.040 |
Why?
|
| Luciferases | 2 | 2011 | 445 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 176 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 314 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 671 | 0.040 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2017 | 21 | 0.040 |
Why?
|
| Time | 1 | 2017 | 178 | 0.040 |
Why?
|
| Epistasis, Genetic | 1 | 2017 | 119 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 348 | 0.040 |
Why?
|
| DEAD Box Protein 20 | 1 | 2016 | 1 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2016 | 75 | 0.040 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 137 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 565 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 292 | 0.040 |
Why?
|
| Viral Core Proteins | 1 | 2016 | 22 | 0.040 |
Why?
|
| Genomic Structural Variation | 1 | 2017 | 77 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 375 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2004 | 806 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 860 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2016 | 112 | 0.030 |
Why?
|
| Protein Array Analysis | 2 | 2011 | 501 | 0.030 |
Why?
|
| Hepatitis B | 1 | 2018 | 258 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 295 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2013 | 1064 | 0.030 |
Why?
|
| Melanoma | 3 | 2013 | 5317 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2009 | 497 | 0.030 |
Why?
|
| Recurrence | 2 | 2016 | 4758 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 858 | 0.030 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 1959 | 0.030 |
Why?
|
| Genes, Reporter | 2 | 2009 | 798 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 338 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2018 | 514 | 0.030 |
Why?
|
| Mucositis | 1 | 2015 | 148 | 0.030 |
Why?
|
| Stomatitis | 1 | 2016 | 183 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 7789 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 7702 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 490 | 0.030 |
Why?
|
| Biotransformation | 1 | 2014 | 93 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 649 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1154 | 0.030 |
Why?
|
| E2F Transcription Factors | 1 | 2014 | 132 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 517 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 236 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 783 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 999 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 276 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 267 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 1085 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 860 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 344 | 0.030 |
Why?
|
| Surgeons | 1 | 2020 | 519 | 0.030 |
Why?
|
| Bilirubin | 1 | 2014 | 221 | 0.030 |
Why?
|
| Veterans Health | 1 | 2014 | 181 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 660 | 0.030 |
Why?
|
| Public Health | 1 | 2015 | 299 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 941 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2012 | 119 | 0.030 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 421 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2013 | 137 | 0.030 |
Why?
|
| Thyroxine | 1 | 2012 | 116 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 3472 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 311 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2012 | 166 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 1230 | 0.030 |
Why?
|
| Vaginal Neoplasms | 1 | 2013 | 152 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1987 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 1283 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 2232 | 0.030 |
Why?
|
| Genome | 1 | 2016 | 672 | 0.030 |
Why?
|
| Aromatase | 1 | 2012 | 56 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 665 | 0.030 |
Why?
|
| Dermatofibrosarcoma | 1 | 2012 | 72 | 0.030 |
Why?
|
| Gonadotropins | 1 | 2012 | 50 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 220 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2013 | 185 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2013 | 299 | 0.030 |
Why?
|
| Reflex, Abnormal | 1 | 2011 | 20 | 0.030 |
Why?
|
| Prolactin | 1 | 2012 | 155 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 1439 | 0.030 |
Why?
|
| Leukoplakia, Oral | 1 | 2011 | 70 | 0.020 |
Why?
|
| Radiography | 1 | 2016 | 1904 | 0.020 |
Why?
|
| Americas | 1 | 2011 | 52 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 966 | 0.020 |
Why?
|
| Ku Autoantigen | 1 | 2011 | 79 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 6089 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2014 | 605 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2012 | 204 | 0.020 |
Why?
|
| Voice Quality | 1 | 2011 | 33 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2012 | 275 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2011 | 241 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 703 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 611 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 3033 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1819 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 430 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2010 | 348 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 60 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 699 | 0.020 |
Why?
|
| Speech Production Measurement | 1 | 2009 | 17 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2009 | 40 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 402 | 0.020 |
Why?
|
| Beer | 1 | 2008 | 4 | 0.020 |
Why?
|
| Osteonecrosis | 1 | 2009 | 53 | 0.020 |
Why?
|
| Wine | 1 | 2008 | 19 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 5159 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2022 | 3341 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2012 | 739 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 2588 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 598 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 4744 | 0.020 |
Why?
|
| North America | 1 | 2009 | 314 | 0.020 |
Why?
|
| Comet Assay | 1 | 2007 | 59 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 227 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2017 | 1330 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 492 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2009 | 483 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2012 | 1014 | 0.020 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2007 | 87 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2011 | 550 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 4307 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 15179 | 0.020 |
Why?
|
| Plasmids | 1 | 2009 | 837 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 15694 | 0.020 |
Why?
|
| Radiation Effects | 1 | 2006 | 20 | 0.020 |
Why?
|
| Guanosine | 1 | 2006 | 22 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2007 | 99 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2007 | 200 | 0.020 |
Why?
|
| Valine | 1 | 2007 | 176 | 0.020 |
Why?
|
| Thymidine | 1 | 2006 | 155 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2009 | 731 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3821 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 2522 | 0.020 |
Why?
|
| HIV Infections | 1 | 2018 | 2134 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 1900 | 0.020 |
Why?
|
| No-Observed-Adverse-Effect Level | 1 | 2005 | 6 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 666 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 644 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3536 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2005 | 42 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2005 | 118 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2006 | 242 | 0.020 |
Why?
|
| Phenotype | 2 | 2008 | 6295 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 953 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2508 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2005 | 133 | 0.020 |
Why?
|
| Calcitriol | 1 | 2005 | 127 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 1618 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 1 | 2004 | 3 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 2074 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 829 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 2004 | 137 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 5395 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2003 | 108 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 4757 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 575 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 176 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2003 | 234 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2003 | 290 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 1472 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 538 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 2370 | 0.010 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2002 | 109 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5178 | 0.010 |
Why?
|
| Animals | 2 | 2017 | 59536 | 0.010 |
Why?
|
| Reoperation | 1 | 2004 | 1382 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 2278 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 2518 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1429 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 3869 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 4938 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 34495 | 0.010 |
Why?
|